Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer

IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials.

HOLLISTON, Mass., Dec. 28, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB:BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or birth defects, today announced that it had selected IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (CRO) to manage its first clinical trial.